Floatz logo

Recombinant Human Interleukin-18

Ovarian, Fallopian Tube and Peritoneal Cancer

Abramson Cancer Center at Penn MedicinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Ovarian, Fallopian Tube and Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Recombinant Human Interleukin-18 is also rated in:

melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
Neoplasms, OvarianDormant
CC
Indicative ·
47 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →